Drug Competition Enhancement Act

Bill Number

S. 1040

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-04-10: Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.

Last Updated

2025-07-21T19:32:26Z

AI-Generated Summary

Purpose

The Drug Competition Enhancement Act (S. 1040) aims to prevent "product hopping" by pharmaceutical manufacturers. Product hopping occurs when a company modifies or reformulates an existing drug (a "follow-on product") and then disadvantages or withdraws the original version to delay competition from cheaper generic drugs or biosimilar biological products (close copies of biologic drugs). The goal is to promote competition, potentially lowering drug prices for consumers by ensuring generics and biosimilars can enter the market more easily.

Key Provisions

• Definitions: The bill defines key terms to clarify its scope, including:
• Abbreviated new drug application (ANDA): A streamlined FDA approval process for generic drugs that are equivalent to an existing brand-name drug.
• Biosimilar biological product: A biologic drug approved as highly similar to an existing one, with no significant differences in safety or effectiveness.
• Follow-on product: A modified or reformulated version of the manufacturer's own previously approved drug or biologic that treats the same or very similar condition.
• Hard switch: Withdrawing FDA approval for the original drug, discontinuing production, or destroying inventory in a way that blocks generics/biosimilars, while marketing the follow-on product.
• Soft switch: Taking other actions (not as extreme as a hard switch) that unfairly disadvantage the original drug compared to the follow-on product, impeding generic/biosimilar competition.
• Excludes changes requested by the FDA or required by law for safety or other reasons.

• Prohibition: During a window starting when a manufacturer learns of a pending generic or biosimilar application and ending either 180 days after the generic/biosimilar launches or 3 years after the follow-on product launches (whichever is sooner), product hopping is deemed an "unfair method of competition" under the Federal Trade Commission (FTC) Act. This applies if the manufacturer engages in a hard or soft switch.

• Exclusions and Justifications:
• Allowed: Truthful, non-misleading advertising or simply stopping promotion of the original drug.
• Manufacturers can defend actions by showing they were unrelated to generic/biosimilar entry and due to safety risks, unavoidable supply issues, or legitimate business reasons (not just to avoid competition). The FTC can challenge these defenses by proving anticompetitive effects outweigh benefits or less harmful alternatives exist.

• Enforcement:
• The FTC can investigate, issue cease-and-desist orders, seek temporary or permanent court injunctions, and pursue remedies like disgorgement (forcing repayment of ill-gotten gains) or restitution (compensating harmed parties).
• Time limit: Actions must be brought within 5 years of the violation's effects.
• Judicial review: Manufacturers can appeal FTC orders to federal courts of appeals within 30 days; FTC factual findings are binding if evidence-supported.
• The bill does not limit FTC's existing powers and allows rulemaking to clarify undefined terms.

• Applicability: Covers conduct and legal actions starting on or after the bill's enactment date. It supplements but does not replace antitrust laws.

Significant Changes to Existing Law

• Adds a new Section 27 to the Federal Trade Commission Act (15 U.S.C. 41 et seq.), explicitly labeling product hopping as an unfair competitive practice. Previously, such behavior was challenged only under general antitrust laws (e.g., Sherman Act) or FTC Section 5, which required proving broader market harm. This creates a clearer, faster "prima facie" (initial presumption) violation standard, easing FTC enforcement without needing full antitrust proof.
• Introduces specific timelines, definitions, and remedies tailored to pharmaceuticals, filling gaps in prior laws like the Hatch-Waxman Act (which governs generic approvals) and the Biologics Price Competition and Innovation Act (for biosimilars).

Potential Impacts

• Government Agencies: Empowers the FTC to more actively regulate pharmaceutical competition, potentially increasing investigations and litigation. The FDA's role remains advisory (e.g., in withdrawals), but coordination with FTC could rise.
• Citizens: Could reduce drug costs by accelerating generic and biosimilar market entry, benefiting patients and payers like insurers and Medicare. However, it might slow legitimate drug innovations if manufacturers fear enforcement.
• International Relations: Minimal direct impact, but could affect U.S.-based operations of global pharmaceutical firms, encouraging fairer practices in international supply chains. No explicit effects on trade agreements.

Main Stakeholders Affected

• Brand-Name Pharmaceutical Manufacturers: Primary targets; face new restrictions and penalties for product strategies, potentially limiting revenue protection from generics/biosimilars.
• Generic and Biosimilar Manufacturers: Benefit from easier market access, enabling faster competition and lower prices.
• Consumers and Patients: Gain from potential price reductions on essential medications, though access to new formulations might be indirectly affected.
• Federal Trade Commission (FTC): Gains expanded authority and tools to enforce competition in the $500+ billion U.S. drug market.
• Healthcare Payers (e.g., Insurers, Government Programs): Could see cost savings, reducing burdens on programs like Medicaid.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens FTC's administrative powers with tailored remedies like disgorgement, but preserves judicial oversight to prevent overreach. It avoids preempting state laws or private antitrust suits, promoting consistency in enforcement.
• Constitutional: No major issues identified; balances competition promotion with First Amendment protections by excluding truthful marketing. Could face challenges if manufacturers argue it unduly burdens innovation (protected under patent rights), but justifications provision mitigates this.
• Political: Bipartisan support (sponsored by Sens. Cornyn, Blumenthal, Grassley, Durbin from both parties) signals broad consensus on curbing drug pricing abuses. May influence ongoing debates on healthcare affordability without broader reforms like price controls, positioning it as a targeted antitrust tool in a polarized Congress.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. Cornyn, John [R-TX]

Cosponsors (3)

Sen. Blumenthal, Richard [D-CT], Sen. Grassley, Chuck [R-IA], Sen. Durbin, Richard J. [D-IL]

Recent Actions

• 2025-04-10: Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
• 2025-04-10: Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.
• 2025-04-10: Committee on the Judiciary. Reported by Senator Grassley with an amendment. Without written report.
• 2025-04-03: Committee on the Judiciary. Ordered to be reported with an amendment favorably.
• 2025-03-13: Read twice and referred to the Committee on the Judiciary.
• 2025-03-13: Introduced in Senate

Bill Versions

• Drug Competition Enhancement Act — issued 2025-03-13 — PDF (15 pages)
• Drug Competition Enhancement Act — issued 2025-04-10 — PDF (16 pages)